Immatics NV

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Tuebingen , Germany and Houston, TX , March 2 3 , 20 2 2 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2021.

Immatics Announces Full Year 2021 Financial Results and Corporate Update

Tuebingen , Germany and Houston, TX , November 16 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress over the reporting period.

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

Company to host conference call on Tuesday, November 9 at 8:30 am EST

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on its ACTengine® IMA203 trial in a late-breaking oral presentation as well as an update on Immatics' next-generation CD8ab TCR-T approach at the 36th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC). The conference will take place, both in person and virtually, from November 10 - 14, 2021.

Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer's 36th Annual Meeting

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Immatics (IMTX) Stock Jumps 5.8%: Will It Continue to Soar?

Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 21.62% year over year to ($0.45), which missed the estimate of ($0.40).

Immatics: Q2 Earnings Insights

Tuebingen, Germany and Houston, TX, August 10, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting period.

Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs).

BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions

BASEL, Switzerland and TÜBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences companies, announced today that they have signed service agreements with Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies. The agreements focus on using integrated services from Selexis and KBI as part of Immatics' development of TCR Bispecifics, called TCER® (T Cell Engaging Re

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced changes to its Board of Directors. Christof Hettich, L.L.D., Managing Partner and founding member of the dievini Hopp BioTech holding GmbH & Co. KG, has decided to step down from Immatics' Board of Directors. He has been a member of Immatics' Board of Directors since 2006. Former Immatics Board member Friedrich von Bohlen und Halbach, PhD, Managing Partner and co-founder of dievini Hopp BioTech Holding GmbH & Co. KG has been nominated to be his successor. The election will take place at Immatics' Annual General Meeting on June 17, 2021.

Immatics Announces Changes to its Board of Directors

Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended March 31, 2021.

Immatics Announces First Quarter 2021 Financial Results and Business Update

Immatics' second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor model

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

The stock price of Immatics N.V. (NASDAQ: IMTX) increased by over 5% pre-market.

IMTX Stock Price Increased Over 5% Pre-Market: Why It Happened

Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2020.

Immatics Announces Full Year 2020 Financial Results and Corporate Update

Adicet Bio, Inc.

Editas Medicine

Sesen Bio Inc.

Sanofi

Shattuck Labs

LAVA Therapeutics has filed to raise $101 million in an IPO.

LAVA Therapeutics Seeks $101 Million U.S. IPO

The stock price of Immatics N.V. (NASDAQ: IMTX) increased by over 58% during intraday trading.

IMTX Stock Price Increased Over 58% Intraday: Why It Happened

A press release from the company is showing promise in shrinking cancerous tumors. The discoveries are leading to a rise in IMTX stock.

IMTX Stock: Why Immatics Shares Are Rocketing Higher Today

Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203. Data showed that first anti-tumor activity with 9 out of 10 evaluable patients showing disease control.

Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients

bluebird bio

FSD Pharma

Onconova Therapeutics

bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.

Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday

FibroGen

Replimune Group Inc

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fundamentals, key make-or-break events and cash runway — can fetch disproportionate returns.

3 Biotech Stocks That Could Double In 12 Months

News for Immatics NV Stock (IMTX)